All You Would Ever Want to Know about Urine Toxicology Screening Mohammad Al-Ghoul, PhD Chief Technical Officer Diane A. Tennies, PhD Lead TEAP Health.

Slides:



Advertisements
Similar presentations
When You Need Results…Now! accutest ® ACCUTEST 5 - Drug Test Cup (Urine)
Advertisements

Presenters: Promoting Regulatory Excellence Use of Substance Abuse Testing in Licensure Actions Donna R. Smith, PhD FirstLab, Inc.
1 USG-755 Drug test Global Security. 2 For easy roadside drug testing DrugWipe 5+ is the enhanced version of the proven saliva test. Featuring an integrated.
We are the thousands of women and men who work for the signatory contractors, suppliers and skilled trade building industry unions in our region.
Laboratory Issues Enabling Learning Objectives
The Medical Review Officer: An Addiction Medicine Perspective CSAM October 9, 2004 By David E. Smith, M.D. Past President, CSAM Past President, ASAM.
Oral Fluid Collection/Screening Training for Line Staff.
Training Program Version 3.06 Use Page-up and Page-down to scroll through the slide show EZ-Cup Drug Screen The EZ-Cup Drug Screen is only a preliminary.
CDD Updates on Specimen Collection & Processing
Iowa Methodist Medical Center Drug Screening. Tests available Drug Screen, Limited, Urine Drug Screen, Urine, Monitoring Sympathomimetic Amines (Amphetamine/
Given a scenario determine if one Soldier is more positive than another. BackNext Nanogram Levels Enabling Learning Objective.
Prescription Drug Abuse And The Toxicology Of Medication Monitoring
OSBI Toxicology Lab Current Technologies for Blood Testing
Drug Utilization Review (DUR)
© 2013 The McGraw-Hill Companies, Inc. All rights reserved. Chapter 9 Tests, Procedures, and Codes.
WELCOME! DRUG TESTING TRAINING. PRE-TEST 1.Each State agency is required or not required to implement a drug testing policy. (Circle One) 2.Substance.
1-3-2 Back 1. State the responsibilities of the Commander, UPL, and observer. 2. Select from a list, responsibilities of the ADCO, PC, EAPC, CD, and MRO.
Advanced Drug Detection Questions & Answers
Urine Drug Testing Why we do it When we do it How we do it What do we test for Problems & Limitations.
By: Paul L. Cary Toxicology Laboratory University of Missouri
Guidelines for Laboratory Testing and Result Reporting for Antibody to Hepatitis C Virus Miriam J. Alter, Ph.D. Division of Viral Hepatitis Centers for.
Forensic Drug Analysis ON-SITE DRUG TESTS SCREENING TESTS
1 Drug-Free Partnership ScreenSafe, Inc
Practicalities of Conducting Biological Assessments for Drug Use Kenzie L. Preston, Ph.D. Chief, Clinical Pharmacology and Therapeutics Research Branch.
FDA Recalls Risk Communication Advisory Committee David K. Elder Director, Office of Enforcement.
Drugs of Abuse Testing Facts and Myths Mohammad Al-Ghoul, PhD Chief Technical Officer Diane A. Tennies, PhD Lead TEAP Health Specialist, Humanitas.
Immunoassays Group 1: Kateryna Dyakiv, Emina Hodzic, Chris Mecinski, Nicholas Anaya, and Andrew Strmic.
The Science Behind Drugs Testing -Past, Present and Future- Dr Francois Oosthuizen – Senior Chemist & Research Officer, Toxicology laboratory, ChemCentre.
The Drug Czar ‘What a Chemistry Minor in College Gets You’ Or ‘You Can’t Beat a Drug Test’
The Role of the Toxicologists
Update on DOT Drug & Alcohol Testing Programs FL DOE Meeting February 2010 Dr. Donna Smith FirstLab, Inc.
Alcohol & drugs Driver. Name of person who will answer driver questions about the materials Drivers subject to Part 382 1a Information drivers must receive.
Practical guide to the use of urine drug screens in primary care
DUID DETECTION THE PRELIMINARY ROADSIDE DRUG TEST SYSTEM WITH ORAL FLUID (SALIVA)
Theoretical Error Rates of Qualitative UDS Tests for Stimulants Neal Oden, PhD, Paul VanVeldhuisen, PhD, NIDA Data and Statistics Center 2, The EMMES Corporation.
EN46001 llc. llc Horizon Medical Technologies' mission is to distribute quality products that are cost effective and unique to the biomedical and healthcare.
Quality Control Lecture 5
DRUGS OF ABUSE Reynaldo J. Lesaca, M.D. Reynaldo J. Lesaca, M.D.
Legal Applications for Drug and Alcohol Testing Kelly R. Broome ARCpoint Labs
CONTROLLED SUBSTANCES AND ALCOHOL USE TESTING REGULATIONS FOR DRIVERS.
How to Guide In the correct completion of the new Urine Toxicology Service Request Form- RANDOM Testing.
CESAR FAX U n i v e r s i t y o f M a r y l a n d, C o l l e g e P a r k A Weekly FAX from the Center for Substance Abuse Research The majority of synthetic.
CONTROLLED SUBSTANCES AND ALCOHOL USE TESTING REGULATIONS FOR DRIVERS.
Toxicology. What is Toxicology? A diagnostic test that examines urine for the presence of prescription or illicit drugs.
Alcohol and Drug Testing
QC/QA.
FDA job description  Regulates about 25% of all consumer purchases  Mission summary: protect and advance public health  Products: food, cosmetics, drugs,
1 SAMPLE ALTERNATIVES URINE BLOOD BREATH SALIVA HAIR SWEAT.
Pathology & Laboratory Medicine Clinical Mass Spectrometry and Toxicology Lab Facts! We are 14 licensed Laboratory Technologists with degree backgrounds.
Although drug use has become more accepted among the general public, workplaces worldwide still sometimes require employees to submit to initial or recurring.
How To Pass A Hair Drug Test. What is a Hair Drug Test? As its name connotes, this kind of drug testing uses hair follicles to establish and verify persistent.
NPS and Importance of Information Sharing Dr Richard Stevenson A&E Department, Glasgow Royal Infirmary Dr Hazel Torrance Forensic Medicine and Science.
1 Student Drug Testing Aldine Independent School District Ken Knippel, Assistant Superintendent of Administration Nikki Reid, Coordinator for Safe and.
STATE BAR OF TEXAS ADVANCED FAMILY COURSE: 2015 AUGUST 3-6, 2015 SAN ANTONIO, TEXAS.
Prescription Drug Monitoring Presented by: Len Abbott, Ph.D. Director Science and Technology Kathleen Valentine, General Manager PDM & Toxicology May 14,
Depart. of Pulmonology 백승숙. More than 80% of cases of tuberculosis in the United States –The result of reactivated latent infection –Nearly all these.
Impact of legalized recreational marijuana in Washington State
Overview of NPN Session
Poly-substance Impaired Drivers
Employment Drug Testing
VALIDITY OF A-CASI SELF-REPORTS OF DRUG USE WITH ON-SITE URINE TESTING IN THE GENERAL POPULATION OF PUERTO RICO Cynthia M. Pérez, PhD; Héctor M. Colón,
By: Mohammad Sami Nabi Director, Field Operations Department
Drug Testing for Child Protection
Controlled substance compliance
Choice of Methods and Instruments
USE OF CLINICAL LABORATORY
BJC HealthCare Campus Renewal Project
Workplace Drug and Alcohol Testing
Introduction To Medical Technology
USE OF CLINICAL LABORATORY
Presentation transcript:

All You Would Ever Want to Know about Urine Toxicology Screening Mohammad Al-Ghoul, PhD Chief Technical Officer Diane A. Tennies, PhD Lead TEAP Health Specialist, Humanitas

Keren Herrera, M.Sc, MT (ASCP) Toxicology Supervisor CDD Team Marian Tully, Sr. Account Manager Barbara Castro, Account Manager Veronica Rodriguez, Account Manager

Learning Objectives Recognize the factors which enhance the reliability and validity of the urine toxicology screening process. Identify the factors which constitute barriers to successful completion of the intervention process. Describe the biochemical testing options available from the CDD.

Reliability and Validity of Urine Toxicology Specimen More than 70% of lab errors are due to pre-analytical issues

Pre-Analytical Variables Specimen collection – Adulterated – Diluted – Substituted (Temp) – Volume (QNS) Accessioning - Labeling - Proper labeling - Mismatch labeling CDD WILL NOT SWITCH LABELS FOR TOX TESTING Incorrectly labeled tube

Analytical (Testing Process) Screening and confirmation Controls Monitor positivity rate Monitor screened positives that confirm negative Proficiency testing Monitor percentage of samples resulted as unsuitable for testing

Post Analytical (After Testing) Review of controls for each run Review of all screening results Review of each positive sample before releasing a result An electronic system is in place to prevent reporting mismatched results Investigation conducted as warranted

Urine Drug Testing Limitation Urine drug testing only indicates prior use Not useful for determining: – Time since last use – Extent/frequency of use – Additional use since last positive test – Current impairment

Test Menu Job Corps Toxicology Panel AMP/Meth-AMP Panel Cannabinoids Cocaine Opiate PCP

Testing Methods Screening: Enzyme Immunoassay (EIA) Confirmation: Gas Chromatography/Mass Spectrometry (GC/MS) – “Gold-Standard” for Drug Testing – NO BIOLOGICAL FALSE POSITIVES

Drugs of Abuse (DAU) Drug GroupScreen Cut-off (ng/mL) Confirm Cut-off (ng/mL) Amphetamines / Methamphetamine Cannabinoids (THC)5015 Cocaine Opiates2000 Phencyclidine25 Testing Methods and Cutoffs Regulated by SAMHSA (Substance Abuse and Mental Health Services Administration)

Factors That May Affect Test Results Drug concentration in urine vary greatly based on: – Individual metabolism – Body composition – Time/Frequency of use – Potency of Drug – Current Hydration Status Dehydrated = higher relative level Over-hydrated = dilution effect

Cannabinoids THC is lipophillic – Fat-soluble Drug levels typically reduced by half in 24 – 48 hours (half-life) Increased time to clear from system relative to other drugs creates challenges Heavy users should clear THC in 30 days Most subsequent positives due to additional use

THC Detection Time THC detection time based on daily usage of 2000 ng/mL Usage at 1 time only5-8 days Usage 2-4 times per month11-18 days Usage 2-4 times per week23-35 days Usage 5-6 times per week33-48 days

Cannabinoids Highly unlikely for an individual to test positive (50 ng/mL) for THC by urine immunoassay through passive exposure Addition of Visine eye drops to urine samples has been shown to cause false-negative results for THC.

Drugs of Abuse (DAU) Drug GroupWindow of detection Amphetamines / Methamphetamine 2-4 days Cannabinoids (THC)1-30 days Cocaine< 72 hours Opiates2-5 days Phencyclidine< 3 days Kaplan and Pesce, Clinical Chemistry, Fourth edition, P1008.

Summary of Agents Contributing to Positive Results by Screening

Conclusion Screening: presumptive only Confirmatory test (GC-MS) is required limitations of urine drug screens – time since last ingestion – overall duration of abuse – state of intoxication Accurate interpretation of results

Questions from the Field Does CDD do any research into drug trends and make recommendations to their clients about what drugs they should be testing for? Answer: Yes and the best example is synthetic cannabinoids (Spice)

Questions from the Field Regarding synthetic cannabinoids: Since the CDD made this test available, how often are centers requesting this additional testing? Answer: About tests/week What percentage of the tests are positive? Answer: Positivity rate of 4-5 %

Questions from the Field Which synthetic cannabinoids are tested for? Answer: Spice only (three metabolites two for JWH-18 and JWH-073) Would the test detect those Synthetic cannabinoids currently marketed as “JWH-free”? Answer: No the test would not detect metabolites other than JWH.

Other Tests Available Spice Screen (Synthetic Cannabinoids) – Patient results report

Questions from the Field What is meant by “cut-off levels”? Answer: Cut-off levels are the minimum levels of drug detected in the sample. This is established by SAMHSA and determines when a test is considered “a positive.”

Questions from the Field I keep getting an “insufficient amount to test” notification. What does that mean, especially when the vial is filled up fully with urine? Answer: This is most likely related to opiate testing. Opiate confirmation testing is performed at our reference laboratory, and in certain situations, they may need more sample for more testing.

Questions from the Field Is there a way centers can access the cumulative data regarding their drug screening (such as the percentage testing positive on entrance and at 45 days) before the Annual Health and Wellness report is published? Answer: No, neither CDD nor Humanitas can make this data available to centers.

Questions from the Field Are creatinine-adjusted levels utilized for more concentrated urine samples to better monitor drug usage? Answer: Not on every sample, only on samples believed to be diluted.

Questions from the Field Why does it take longer for some drugs to go through the confirmation process? Answer: Some tests take longer to process for confirmation testing than others. Other tests are send to a reference laboratory for testing, thus taking longer for the results to be reported back to centers.

Questions from the Field Is there anyway we can know if a student is over ng? Answer: No because our technical and instrument capabilities are limited to 800ng/ml. Any amount above this is reported as >800ng/ml.

Questions from the Field Given the low incidence of PCP in this population, why do we continue to test for this drug? Answer: This is not CDD’s decision, these are the recommendation of SAMHSA, they are the only entity who would have to decide whether we should stop testing for it or not.

Questions from the Field Why don’t we test for opioids such as oxycodone? Is there a plan to offer a test for synthetic opiates? Answer: CDD does offer the option to order opioids (synthetic opiates), however the testing is performed at our reference laboratory.*

Questions from the Field Does CDD have a test for other synthetic drugs, such as “Bath Salts”? Answer: Not at the present time but we are evaluating the need to make this test available. If this test become available then a mass will be sent to centers.

Questions from the Field Are Adderall and Concerta (and their derivatives) detected in the tox screen? Answer: Adderall is an amphetamine-based drug, so yes, it would be detected. Concerta is not an amphetamine-based drug and does not cross react with the amp/meth panel.

Conclusions More Questions and Comments? Final Thoughts from the CDD